ARB and CCB Longest Combination Treatment on Ambulatory and Home BP in Hypertension With Atrial Fibrillation -Multicenter Study on Time of Dosing (ACROBAT)

Study Overview
=================
Brief Summary
-----------------
Evaluation of 24-hour antihypertensive effect of long-acting ARB-CCB tablet administrated to hypertensive patients with atrial fibrillation, and comparison of 24-hour antihypertensive effect of long-acting ARB-CCB tablet between morning administration and bedtime administration.

Official Title
-----------------
ARB and CCB Longest Combination Treatment on Ambulatory and Home BP in Hypertension With Atrial Fibrillation -Multicenter Study on Time of Dosing

Conditions
-----------------
Hypertension and Atrial Fibrillation

Intervention / Treatment
-----------------
* Drug: Telmisartan-amlodipine tablet administration group (morning)
* Drug: Telmisartan-amlodipine tablet administration group (bedtime)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hypertensive patients who meet the following conditions: Patients who meet any of the following standards of blood pressure after administration of 40 mg/day telmisartan or 5 mg/day amlodipine for 4 weeks: - Blood pressure at hospital visit: Systolic blood pressure is 140 mmHg or higher, and/or diastolic blood pressure is 90 mmHg or higher. (average of 3 measurements obtained at a scheduled visit) - Blood pressure at home: Systolic blood pressure is 135 mmHg or higher, and/or diastolic blood pressure is 85 mmHg or higher. (average of measurements for the 5 days prior to drug assignment [4 measurements per day in total: 2 in the morning and 2 before bedtime]) Patients with atrial fibrillation detected on an electrocardiogram within the last 2 years prior to obtaining informed consent. Age: 20 years old or older (at time of informed consent) Sex: male or female Clinical classification: Outpatient Patients who give written consent of agreement to voluntarily participate in the clinical study. Exclusion Criteria: Patients with serious liver and/or kidney disease Patients with history of allergy to telmisartan or amlodipine Patients receiving antihypertensives other than telmisartan or amlodipine during observation period Patients diagnosed with persistent atrial fibrillation or chronic (permanent) atrial fibrillation. Patients with atrial fibrillation caused by irreversible illness (e.g., heart surgery, pulmonary embolism, or hyperthyroidism) Patients with average systolic blood pressure at hospital visit higher than 180 mmHg during observation period. Patients with New York Heart Association (NYHA) class III-IV heart failure, patients with heart failure requiring hospitalization, or patients with poor left ventricular function. Patients who have stroke or cardiac infarction within 6 months before giving consent. Patients planning to undergo pulmonary artery ablation surgery or any surgical procedure (including PCI). Patients who are breast-feeding, pregnant, possibly pregnant, or plan to become pregnant. In addition, patients who are determined as not eligible by their study doctor.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Telmisartan-amlodipine tablet administration group (morning)<br> | Drug: Telmisartan-amlodipine tablet administration group (morning)<br>* Oral-administration of one telmisartan-amlodipine tablet once a day upon morning for 12 weeks<br>|
| Active Comparator: Telmisartan-amlodipine tablet administration group (bedtime)<br> | Drug: Telmisartan-amlodipine tablet administration group (bedtime)<br>* Oral-administration of one telmisartan-amlodipine tablet once a day at bedtime for 12 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in 24-hour average blood pressure from baseline to Week 12. |  | Baseline and 12 weeks. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in blood pressures at night time, early-morning, and daytime from baseline to Week 12. |  | Baseline and 12 weeks. | 
| Change in blood pressure at hospital visit from baseline to Week 12. |  | Baseline and 12 weeks. | 
| Change in blood pressure at home from baseline to Week 12. |  | Baseline and 12 weeks. | 
| Change in blood pressure control rate from baseline to Week 12. |  | Baseline and 12 weeks. | 
| Change in blood pressure variability from baseline to Week 12. |  | Baseline and 12 weeks. | 
| Change in laboratory parameters (blood insulin, hsTnT, PAI-1, and NT-ProBNP) from baseline to Week 12. |  | Baseline and 12 weeks. | 
| Onset of Adverse events |  | Baseline and 12 weeks. | 
| Onset of atrial fibrillation |  | Baseline and 12 weeks. | 
| Pulse rate |  | Baseline and 12 weeks. | 
| PWV value |  | Baseline and 12 weeks. | 
| Clinical laboratory test results |  | Baseline and 12 weeks. |